8.2.7 Immunotherapy responsive malignancy
| First line drugs | Second line drugs | Specialist drugs | Secondary care drugs |
Traffic light status (TLS) explained:
- Green: Routine prescribing within licensed indication
- Amber 1: specialist recommendation followed by GP initiation and continuation
- Amber 2: specialist or GP initiation in line with local guideline after 1st line failure followed by GP continuation
- Amber 3: specialist initiation and stabilisation followed by GP continuation
- Amber SCG: specialist initiation and stabilisation followed by GP continuation in line with an agreed shared care guideline
- Red: Hospital or specialist prescribing only
Immunomodulating drugs
Mifamurtide
- Intravenous Infusion 4mg vial
Note:
- Use as per NICE TA235: Mifamurtide for the treatment of osteosarcoma (October 2011)
Trifluridine/tipiracil
- Lonsurf® Tablets, 15mg/6.14mg, 20mg/8.19mg
Notes:
- Children: Not recommended
- Use as per NICE TA405: Trifluridine–tipiracil for previously treated metastatic colorectal cancer (August 2016)
Interferons
Interferon Alfa-2a (rbe), Roferon-A®
- Injection, 3 million-unit in 0.5mL pre-filled syringe
- Injection, 3 million-unit in 1mL vial
- Injection, 4.5 million-unit in 0.5mL pre-filled syringe
- Injection, 4.5 million-unit in 1mL vial
- Injection, 6 million-unit in 0.5mL pre-filled syringe
- Injection, 9 million-unit in 0.5mL pre-filled syringe
Note:
- Use as per NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C (January 2004)
Peginterferon Alfa
- Pegasys® Peginterferon alfa-2a Injection,
- 135 microgram pre-filled pen/syringe,
- 180 microgram pre-filled pen/syringe
- ViraferonPeg® Peginterferon alfa-2b (rbe) Injection
- 50 microgram pre-filled pen,
- 80 microgram pre-filled pen,
- 120 microgram pre-filled pen,
- 150 microgram pre-filled pen
Notes:
- Use as per NICE TA300: Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people (November 2013)
- Use as per NICE TA200: Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C (September 2010)
- Use as per NICE TA106: Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C (Last updated: November 2013)
- Use as per NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C (January 2004)
Interferon beta-1a
- Avonex® Injection, 30mcg (6 million-unit) powder and solvent for solution (BIO-SET)
- Avonex® Injection, 30mcg/0.5mL (6 million-unit) solution in Pre-filled syringe
- Avonex® Injection, 30mcg/0.5mL (6 million-unit) solution in Pre-filled pen
- Rebif® Injection, 22mcg (6 million-unit) prefilled syringe or pen
- Rebif® Injection, 44mcg (12 million-unit) prefilled syringe or pen
- Rebif® Injection, 44mcg (12 million-units/mL) 1.5mL (66mcg, 18 million-unit) cartridge
- Rebif® Injection, 88mcg (24 million-units/mL) 1.5mL (132mcg, 36 million-unit) cartridge
Interferon beta-1b
- Betaferon® Injection, 300mcg (9.6 million-unit) powder for reconstitution, vial with diluent
- Extavia® Injection, 300mcg (9.6 million-unit), powder for reconstitution, vial with diluent
Immunotherapies
Bacillus Calmette-Guérin
- ImmuCyst® bladder instillation 81mg vial
- OncoTICE® bladder instillation 12.5mg vial
Thalidomide and related anologues
Lenalidomide
- Capsules 5mg, 10mg, 15mg, 25mg
Notes:
- Use as per NICE TA587: Lenalidomide plus dexamethasone for previously untreated multiple myeloma (June 2019)
- Use as per NICE TA586: Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib (June 2019)
- Use as per NICE TA322: Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality (September 2014)
- Use as per NICE TA171: Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy (Last updated: 01 April 2014)
Pomalidomide
- Imnovid® Capsules 1mg, 2mg, 3mg, 4mg
Note:
- Use as per NICE TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib(January 2017)
Thalidomide
- Capsules 50mg
Notes:
- Original pack prescribing / dispensing only; Patient, prescriber, and supplying pharmacy must comply with a pregnancy prevention programme. Every prescription must be accompanied by a complete Prescription Authorisation Form
- Thalidomide: reduced starting dose in patients older than age 75 years (Last updated December 2015)
- Use as per NICE TA228: Bortezomib and thalidomide for the first?line treatment of multiple myeloma (July 2011)
- Thalidomide in combination with an alkylating agent and a corticosteroid is recommended as an option for the first-line treatment of multiple myeloma in people for whom high-dose chemotherapy with stem cell transplantation is considered inappropriate.
Others
Tisagenlecleucel
- single-dose intravenous infusion
Notes:
- Use as per NICE TA567: Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (March 2019)
- Use as per NICE TA554 Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years (December 2018)
Traffic light status (TLS) explained:
- Green: Routine prescribing within licensed indication
- Amber 1: specialist recommendation followed by GP initiation and continuation
- Amber 2: specialist or GP initiation in line with local guideline after 1st line failure followed by GP continuation
- Amber 3: specialist initiation and stabilisation followed by GP continuation
- Amber SCG: specialist initiation and stabilisation followed by GP continuation in line with an agreed shared care guideline
- Red: Hospital or specialist prescribing only
Return to Chapter: 8. Immune System and Malignant Disease
Last updated by: Sheila Wood on 06-08-2019 12:27
-
BNF
-
NICE
-
Summary of product characteristics
